EUVIMEDEUVIMED entdecken
Crossref

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials

Kenta Iguchi, Kentaro Yamazaki, Toshihiro Misumi, Hideaki Bando, Yuka Nishimura, Tomomi Nishikawa, Eiji Oki, Jean-Yves Douillard, Miriam Koopman, Eric Van Cutsem, Carsten Bokemeyer, Alan P Venook und 8 weitere

European Journal of Cancer · 2026-08 · 244 · 116886

DOI: 10.1016/j.ejca.2026.116886 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-08. Verfasst von Kenta Iguchi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, ErbB Receptors, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Immunological. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The selection of biologic therapies in metastatic colorectal cancer (mCRC) is traditionally guided by right-left classification; however, this binary classification may not fully capture heterogeneity in responsiveness to anti-epidermal growth factor receptor (EGFR) therapy. We evaluated whether treatment efficacy varies across detailed anatomical tumour segments. METHODS: Individual patient-level data from 12 randomised controlled trials in the ARCAD database were analysed. Patients with RAS wild-type (RAS-WT) mCRC receiving first-line doublet chemotherapy plus anti-EGFR therapy or bevacizumab were included. The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS) and objective response rate (ORR). RESULTS: A total of 2867 patients were included (815 right-sided colon cancer [RSC]; 2052 left-sided colorectal cancer [LSC]). In RAS-WT RSCs, anti-EGFR therapy was not associated with improved OS or PFS versus bevacizumab. In RAS/BRAF-WT RSCs, anti-EGFR therapy was associated with inferior PFS. In contrast, in RAS-WT LSCs, anti-EGFR therapy significantly improved OS and ORR, without a significant difference in PFS. Segment-level analyses (N = 1491) showed no significant heterogeneity within RSCs, although median OS numerically varied across subsites. Within LSCs, the OS benefit was most pronounced in the rectum. CONCLUSIONS: The efficacy of anti-EGFR therapy in mCRC appears to exhibit additional intraregional heterogeneity beyond the conventional right-left classification. These findings suggest that anatomical tumour location may reflect underlying biological differences not fully captured by this binary classification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsErbB ReceptorsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, ImmunologicalHumansRandomized Controlled Trials as TopicFemaleBevacizumabMaleMiddle AgedAgedTreatment Effect HeterogeneityProgression-Free SurvivalCetuximab

Stichwörter der Autor:innen

Anti-epidermal growth factor receptor antibodiesMetastatic colorectal cancerPooled analysisRAS wild-typeTumour location

Substanzen

ErbB ReceptorsAntineoplastic Agents, ImmunologicalBevacizumabEGFR protein, humanCetuximab

Autor:innen und Institutionen

  • Department of Colorectal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan. Electronic address: k.yamazaki1121@gmail.com.
  • Department of Data Science, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Data Science, National Cancer Center Hospital East, Chiba, Japan; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer, Center Hospital East, Chiba, Japan.
  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • University of Nantes Medical School Nantes, France.

Zitieren

APA

Iguchi, K., Yamazaki, K., Misumi, T., Bando, H., Nishimura, Y., Nishikawa, T., Oki, E., Douillard, J. Y., Koopman, M., Van Cutsem, E., Bokemeyer, C., Venook, A. P., Maehara, Y., Heinemann, V., Cremolini, C., Nakayama, G., André, T., Shi, Q., de Gramont, A., & Yoshino, T. (2026). Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials. European Journal of Cancer, 244, 116886. https://doi.org/10.1016/j.ejca.2026.116886

Vancouver

Iguchi K, Yamazaki K, Misumi T, Bando H, Nishimura Y, Nishikawa T, et al. Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials. European Journal of Cancer. 2026;244:116886. doi:10.1016/j.ejca.2026.116886

BibTeX
@article{Iguchi2026,
  author = {Iguchi, Kenta and Yamazaki, Kentaro and Misumi, Toshihiro and Bando, Hideaki and Nishimura, Yuka and Nishikawa, Tomomi and Oki, Eiji and Douillard, Jean-Yves and Koopman, Miriam and Van Cutsem, Eric and Bokemeyer, Carsten and Venook, Alan P and Maehara, Yoshihiko and Heinemann, Volker and Cremolini, Chiara and Nakayama, Goro and André, Thierry and Shi, Qian and de Gramont, Aimery and Yoshino, Takayuki},
  title = {Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {244},
  pages = {116886},
  doi = {10.1016/j.ejca.2026.116886}
}
Kostenlos starten →